Quantcast

Latest International AIDS Vaccine Initiative Stories

2011-07-19 00:00:00

Flexible, agile and generous funding structures needed to ensure development and delivery of lifesaving new options for HIV prevention ROME, July 19, 2011 /PRNewswire-USNewswire/ -- In the last year, promising trial results and critical scientific breakthroughs have changed the HIV prevention landscape, providing new opportunities for both a broader response to the epidemic with new prevention options and broader clinical and laboratory agendas with new research targets. At the same time,...

2011-06-23 07:00:00

ATLANTA, June 23, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today the opening of a third site for testing the therapeutic potential of its HIV/AIDS vaccine. The Los Angeles-based AIDS Research Alliance (ARA) will join with two existing members of GeoVax's clinical trial site team: the AIDS Research Consortium of Atlanta and the Alabama Vaccine Research Clinic at the...

2011-06-08 10:09:00

WASHINGTON, June 8, 2011 /PRNewswire/ -- Fourteen leading scientists and advocacy experts in vaccines and infectious diseases have announced the formation of a new international Foundation to advance and accelerate vaccine research and development against infectious diseases. The Foundation for Vaccine Research will be headquartered in Washington, DC. The Foundation's mission is to raise global awareness of the need for increased, long-term, flexible funding for vaccine research against...

92517c02f30939860d6bc177927f84b0
2011-06-05 09:05:00

Timothy Ray Brown, an HIV-positive American, known as "the Berlin patient," has become an icon for the potential end of a disease that has claimed the lives of countless millions, and has also become a sign of hope for scientists who are trying to end the AIDS pandemic.Remarkable scientific advances since HIV was first discovered 30 years ago this week mean the virus is no longer a death sentence. Thanks to tests that detect HIV early on, new drugs that have been developed that can control...

2011-05-18 14:17:20

In honor of HIV Vaccine Awareness Day, researchers at Baylor College of Medicine will host a community open house on Wednesday, May 18, at 7 p.m. at the Houston GLBT Community Center, 1900 Kane Street, Houston, TX 77007. The event is open to the public and will include a presentation on the state of HIV vaccine research, including a vaccine trial currently going on at BCM. The study is being conducted by the HIV Vaccine Trials Network, and Baylor is one of 15 sites across the country...

2011-05-12 00:03:55

Research conducted at Oregon Health & Science University's Vaccine and Gene Therapy Institute (VGTI) has developed a vaccine candidate in non-human primates that may eventually lead to a vaccine against Human Immunodeficiency Virus (HIV). Details of this advance are published in the advance online edition of the journal Nature. The paper will also be published in an upcoming print addition of the journal. The research team, led by Louis Picker, M.D., associate director of the OHSU VGTI...

2011-05-04 15:05:00

ATLANTA, May 4, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCBB: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today released its 2010 Annual Report and President's Letter to the Company's stockholders. The Annual Report (10-K) provides information on the state of the Company's finances at the conclusion of 2010. In his Letter, GeoVax's President Robert T. McNally, Ph.D., provides a concise overview of the Company's Therapeutic Vaccine...

2011-04-27 15:00:00

ATLANTA, April 27, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCBB: GOVXD), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today announced its financial results for the three months ended March 31, 2011. GeoVax reported a net loss of $606,282 for the three months ended March 31, 2011, compared to $690,789 for the same period in 2010. Net losses were partially offset by grant revenues of $893,002 and $1,338,560 for each period, respectively, related to...

2011-04-07 07:00:00

ATLANTA, April 7, 2011 /PRNewswire/ -- Harriet Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), will provide an update on the status of the Company's therapeutic and preventative HIV vaccines at the 2011 World Vaccine Conference at the Gaylord National Hotel and Convention Center in Washington DC on Thursday, April 14. Dr. Robinson's invited talk, which will run from 11:30 - 11:50 a.m., will cover the topic of recombinant viruses as vaccines. The talk...

2011-02-09 06:30:00

ATLANTA, Feb. 9, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today the opening of a second clinical trial site at the Alabama Vaccine Research Clinic (AVRC) of the University of Alabama at Birmingham (UAB) to expand the company's HIV therapeutic vaccine trial. Although the GeoVax vaccines are currently being tested clinically for HIV prevention, this is the first clinical...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.